Physician profile
Ana E Davis
NPI 1629403100
$4,922.38
in general payments reported to CMS, 2019-2025
11 companies · $774 in 2025
The $774 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,181 · 2022: $620 · 2023: $1,240 · 2024: $1,107 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,023.33 | 2021-2025 | Gallant, Ensite Precision, Assurity |
| Boston Scientific Corporation | $979.72 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Accolade Sr, General - Brady |
| Medtronic, INC. | $942.74 | 2022-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Mycarelink |
| Lantheus Medical Imaging, INC. | $366.68 | 2021-2024 | Definity |
| Teleflex LLC | $138.07 | 2024-2025 | Chocolate, Turnpike, Trapliner |
| Cmp Pharma, INC. | $136.89 | 2021-2023 | Carospir, Norliqva, Tadliq |
| Amgen INC. | $126.63 | 2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $116.50 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $42.20 | 2021 | |
| Cardiva Medical, INC. | $31.09 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Novo Nordisk INC | $18.53 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.